Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TRON Group
Alachua, Florida, United Statesnanopharmaceutics.com ↗
- Ownership
- Public · TGRP
- Employees
- ~50
- Development stage
- Other
01
Overview
TRON Group, through subsidiaries including Nanopharmaceutics, is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable small molecule products for cancer, CNS disorders, diabetes, and infectious diseases, leveraging nanoparticle and fine-particle formulations; its lead assets include Triapine for cancer and other partnered and proprietary clinical-stage programs across oncology, CNS, and infectious disease indications.[2][5][1]
- Therapeutic areas
- EndocrinologyNeurologyInfectious DiseasesPsychiatryOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Financials
- Market cap
- $6.6M
- Total revenue
- $2.8M
- Enterprise value
- $11.4M
Beyond the preview
Go deeper on TRON Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRON Group.